6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications.
about
6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosynthesesImaging of gastroenteropancreatic neuroendocrine tumorsImaging biomarkers in primary brain tumours.Imaging of transplanted islets by positron emission tomography, magnetic resonance imaging, and ultrasonographyItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-5-[(18)F]fluoro-2-methylpentanoic Acid ((R)-, (S)-[(18)F]FAMPe) as Potential Positron Emission Tomography Tracers for Brain Tumors.Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors.Total Radiosynthesis: Thinking outside "the box"PET designated flouride-18 production and chemistryA clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imagingImaging the islet graft by positron emission tomography.Non-FDG PET in oncology.Chiral nickel(II) complexes in the preparation of 11C- and 18F-labelled enantiomerically pure α-amino acids.Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis.Role of PET/CT in the functional imaging of endocrine pancreatic tumors.Molecular imaging of adrenal neoplasms.Congenital hyperinsulinism: Role of fluorine-18L-3, 4 hydroxyphenylalanine positron emission tomography scanning.Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.Neuroendocrine Testicular Tumors: A Systematic Review and Meta-Analysis.Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes.Impact of residual (18)F-fluoride in (18)F-FDOPA for the diagnosis of neuroblastoma.Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic studyFluorine-18 labeled amino acids for tumor PET/CT imaging[18F]fluorination of an arylboronic ester using [18F]selectfluor bis(triflate): application to 6-[18F]fluoro-L-DOPA.The Added Diagnostic Value of 18F-Fluorodihydroxyphenylalanine PET/CT in the Preoperative Work-Up of Small Bowel Neuroendocrine Tumors.Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors.Carbidopa-assisted 18F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors.Enhanced copper-mediated (18)F-fluorination of aryl boronic esters provides eight radiotracers for PET applications.Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis
P2860
Q26991479-9CDAE98D-59CA-4273-86DA-941C4194B56AQ28238305-C87C64ED-220C-41D3-A6A4-004581D532FFQ30880129-7233E533-B4B9-497A-9DA3-756F6A215AC4Q33568304-6A661EC6-73B3-4CEE-A8AB-C8CF8FD14EA1Q34157385-BC0736DE-24BB-48F7-8777-971467A61ACFQ34256413-53531EC7-AB81-401A-9A39-7B260041F2F5Q35764792-B4976598-D687-4A4C-880F-D91535769492Q35801361-522E434C-A08D-4D8D-B219-EBCAD240B83EQ35869517-EF54C673-EEE6-474A-8AD3-090190B35CE0Q36029393-E2EC9F7F-159C-444D-8DC2-372060268CB3Q36100908-B156A5AC-099C-4C53-8874-B0E3391DD82DQ36742964-BDA8B36F-48C9-4614-B8DA-47D2E1114CECQ37002905-06A93003-CC4E-48BF-89BB-41B75432438EQ37273065-2703D674-BB4B-404B-BA2C-1212EC3BE2B2Q37935646-BA2DEF2C-F3C1-4569-B5E4-777F870E79BCQ37956045-CC364A34-FF5D-46E2-8E5E-AEED13A2D56FQ37967152-8288D7F5-883A-4193-8C83-0ACE35B0EEBAQ37987448-9170FA19-99F0-4016-A6D3-CD035D230B2BQ37994083-E19F18E2-9DED-4D95-B5EC-C6125A4FB2E4Q38013072-904302C0-0225-48B3-AC62-D6E9E91304D9Q38224478-BE6622E1-90E5-4DB2-9DA6-EF5C968CEB8EQ38476583-9398F75C-AEAE-4027-8DBF-95F36C8BA9A9Q38755385-7F761574-3459-4E05-AD51-1E27B4ED80D4Q38966288-C1B37BF3-4937-4726-AFDA-4658C94CEB47Q39020647-B4F843FA-0FDD-43CC-90E0-993C28D0199FQ41180546-E503C8CE-1D91-4D34-A821-A2E1806AFF3EQ41694062-D8BE510B-3016-4BDC-87E6-B7D25799D3BEQ44562624-E6525826-030D-43C5-80AA-A7C85A7D6ED1Q47319849-7FE290F6-1F16-4CCE-82DA-1EBC197DDDCAQ47833074-095182C1-6380-4363-81D4-42F39A4CCE05Q52965503-7C85804B-F5D6-406C-98EE-D4B72EB8C3BEQ52982638-CA6C5407-E91E-44DD-A5C0-43B82C94CB97Q58005428-76C86F26-80E4-4BB2-964E-C4BEA63C9720
P2860
6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
6-L-18F-fluorodihydroxyphenyla ...... merging clinical applications.
@en
6-L-18F-fluorodihydroxyphenyla ...... merging clinical applications.
@nl
type
label
6-L-18F-fluorodihydroxyphenyla ...... merging clinical applications.
@en
6-L-18F-fluorodihydroxyphenyla ...... merging clinical applications.
@nl
prefLabel
6-L-18F-fluorodihydroxyphenyla ...... merging clinical applications.
@en
6-L-18F-fluorodihydroxyphenyla ...... merging clinical applications.
@nl
P2093
P1476
6-L-18F-fluorodihydroxyphenyla ...... merging clinical applications.
@en
P2093
Adrienne H Brouwers
Christopher J Marriott
Karen Y Gulenchyn
Pieter L Jager
Raman Chirakal
P304
P356
10.2967/JNUMED.107.045708
P407
P577
2008-03-14T00:00:00Z